Jul 2026
Abstract A079: Structure-guided discovery of first-in-class TRIB2 small-molecule inhibitors for therapy-resistant neuroendocrine prostate cancer
These findings establish TRIB2 as a druggable vulnerability in enzalutamide-resistant and NE prostate tumors despite the inherent challenges of targeting pseudokinases.
J. Monga, Sang-Yoon Lee, Deepak Rohila et al.
· Clinical Cancer Research · 0 citations